Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 1, 2013, Pages 102-109

  Saunders, Luke J ^a   Russell, Richard A ^a,b   Kirwan, James F ^c   McNaught, Andrew I ^d   Crabb, David P ^a  

^a CITY UNIVERSITY   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^d CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

Glaucoma; Life expectancy; Perimetry; Visual fields; Visual function

Indexed keywords

EID: 84891888753     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13006     Document Type: Article

References (51)

1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression-results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279.
2. US Social Security Administration. Disability evaluation under Social Security. Available at: http://www.ssa.gov/disability/ professionals/bluebook/2.00-SpecialSensesandSpeech-Adult. htm#203. Accessed January 21, 2013.
3. Heijl A, Aspberg J, Bengtsson B. The effect of different criteria on the number of patients blind from open-angle glaucoma. BMC Ophthalmol. 2011;11:31.
4. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology. 2003;110:726-733.
5. Kwon YH, Kim C, Zimmerman MB, Alward WLM, Hayreh SS. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol. 2001;132: 47-56.
6. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998; 105:2099-2104.
7. Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. Ophthalmology. 2009;116:2271-2276.
8. Medeiros FA, Zangwill LM, Mansouri K, Lisboa R, Tafreshi A, Weinreb RN. Incorporating risk factors to improve the assessment of rates of glaucomatous progression. Invest Ophthalmol Vis Sci. 2012;53:2199-2207.
9. Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian glaucoma study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol. 2010;218:1249-1255.
10. Reis ASC, Artes PH, Belliveau AC, et al. Rates of change in the visual field and optic disc in patients with distinct patterns of glaucomatous optic disc damage. Ophthalmology. 2012;119: 294-303.
11. De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann JM. Glaucoma with early visual field loss affecting both hemifields and the risk of disease progression. Arch Ophthalmol. 2009; 127:1129-1134.
12. Prata TS, De Moraes CG, Teng CC, Tello C, Ritch R, Liebmann JM. Factors affecting rates of visual field progression in glaucoma patients with optic disc hemorrhage. Ophthalmology. 2010;117:24-29.
13. Teng CC, De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann JM. β-Zone parapapillary atrophy and the velocity of glaucoma progression. Ophthalmology. 2010;117:909-915.
14. Heijl A, Buchholz P, Norrgren G, Bengtsson B. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol Scand. 2012;91:406-412.
15. Heijl A. The times they are a-changin': Time to change glaucoma management. Acta Ophthalmol Scand. 2013;91:92-99.
16. Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008;92:569-573.
17. European Glaucoma Society. European Glaucoma Society Guidelines (2008): Terminology and Guidelines for Glaucoma. Savona, Italy: Editrice DOGMA; 2008;117-153.
18. Crabb DP, Garway-Heath DF. Intervals between visual field tests when monitoring the glaucomatous patient: wait and see. Invest Ophthalmol Vis Sci. 2012;53:2770-2776.
19. Jansonius NM. On the accuracy of measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2010;94:1404-1405.
20. Wesselink C, Stoutenbeek R, Jansonius NM. Incorporating life expectancy in glaucoma care. Eye. 2011;25:1575-1580.
21. Wild JM, Dengler-Harles M, Searle AET, O'Neill EC, Crews SJ. The influence of the learning effect on automated perimetry in patients with suspected glaucoma. Acta Ophthalmol Scand. 1989;67:537-545.
22. Heijl A, Lindgren G, Olsson J. The effect of perimetric experience in normal subjects. Arch Ophthalmol. 1989;107: 81-86.
23. Heijl A, Bengtsson B. The effect of perimetric experience in patients with glaucoma. Arch Ophthalmol. 1996;114:19-22.
24. Office of National Statistics. England, Interim Life Tables, 1980-82 to 2008-10. Available at: http://ons.gov.uk/ons/rel/ lifetables/interim-life-tables/2008-2010/rft-ilt-eng-2008-10.xls. Accessed August 31, 2012.
25. Jampel HD, Friedman DS, Quigley HA, Miller R. Correlation of the binocular visual field with patient assessment of vision. Invest Ophthalmol Vis Sci. 2002;43:1059-1067.
26. Hodapp E, Parrish RKI, Anderson DR. Clinical Decisions in Glaucoma. St Louis: The CV Mosby Co.; 1993.
27. Brusini P, Filacorda S. Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma. J Glaucoma. 2006;15:40-6.
28. Susanna R Jr, Vessani RM. Staging glaucoma patient: why and how? Open Ophthalmol J. 2009;3:59-64.
29. Saunders LJ, Russell RA, Crabb DP. Practical landmarks for visual field disability in glaucoma. Br J Ophthalmol. 2012;96: 1185-1189.
30. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available at: http://www. R-project.org.
31. Heijl A, Lindgren G, Olsson J. Normal variability of static perimetric threshold values across the central visual field. Arch Ophthalmol. 1987;105:1544-1549.
32. Turpin A, McKendrick AM. What reduction in standard automated perimetry variability would improve the detection of visual field progression? Invest Ophthalmol Vis Sci. 2011; 52:3237-3245.
33. Russell RA, Crabb DP, Malik R, Garway-Heath DF. The relationship between variability and sensitivity in large-scale longitudinal visual field data. Invest Ophthalmol Vis Sci. 2012; 53:5985-5990.
34. Grant WM, Burke JFJ. Why do some people go blind from glaucoma? Ophthalmology. 1982;89:991-998.
35. Oliver JE, Hattenhauer MG, Herman D, et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol. 2002;133:764-772.
36. Kotecha A, Fernandes S, Bunce C, Franks WA. Avoidable sight loss from glaucoma: is it unavoidable? Br J Ophthalmol. 2012; 96:816-820.
37. Henson DB, Thampy R. Preventing blindness from glaucoma-better screening with existing tests should be the priority. BMJ. 2005;331:120-121.
38. Henson DB, Shambhu S. Relative risk of progressive glaucomatous visual field loss in patients enrolled and not enrolled in a prospective longitudinal study. Arch Ophthalmol. 2006; 124:1405-1408.
39. Kooijman AC, Brouwer WH, Coeckelbergh TRM, et al. Compensatory viewing training improves practical fitness to drive of subjects with impaired vision. Vis Impair Res. 2004;6: 1-27.
40. Kotecha A, O'Leary N, Melmoth D, Grant S, Crabb DP. The functional consequences of glaucoma for eye-hand coordination. Invest Ophthalmol Vis Sci. 2009;50:203-213.
41. Smith ND, Crabb DP, Garway-Heath DF. An exploratory study of visual search performance in glaucoma. Ophthalmic Physiol Opt. 2011;31:225-232.
42. Black AA, Wood JM, Lovie-Kitchin JE. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88:1275-1282.
43. Tabrett DR, Lathan K. Important areas of the central binocular visual field for daily functioning in the visually impaired. Ophthalmic Physiol Opt. 2012;32:156-163.
44. Glen FC, Crabb DP, Smith ND, Burton R, Garway-Heath DF. Do patients with glaucoma have difficulty recognising faces? Invest Ophthalmol Vis Sci. 2012;53:3629-3637.
45. Membrey WL, Poinoosaumy DP, Bunce C, Fitzke FW, Hitchings RA. Comparison of visual field progression in patients with normal pressure glaucoma between eyes with and without visual field loss that threatens fixation. Br J Ophthalmol. 2000; 84:1154-1158.
46. Carl Zeiss Meditec, Inc. Humphrey Glaucoma Progression Analysis. (GPA) Software-An advanced approach to monitoring disease progression. Available at: http://www.zeiss.de/ C125679E00525939/EmbedTitelIntern/OFS_White_ Paper16_eng/$File/OFS_whitepaper16_eng.pdf. Accessed October 6, 2013.
47. Bengtsson B, Patella VM, Heijl A. Prediction of glaucomatous visual field loss by extrapolation of linear trends. Arch Ophthalmol. 2009;127:1610-1615.
48. McNaught AI, Crabb DP, Fitzke FW, Hitchings RA. Modelling series of visual fields to detect progression in normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1995;233:750-755.
49. Bryan SR, Vermeer KA, Eilers PHC, Lemij HG, Lesaffre EMEH. Robust and censored modeling and prediction of progression in glaucomatous visual fields. Invest Ophthalmol Vis Sci. 2013; 54:6694-6700.
50. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol. 2004;242:397-401.
51. Office of National Statistics. Ethnicity and national identity in England and Wales 2011. Available at: http://www.ons.gov.uk/ ons/dcp171776_290558.pdf. Accessed November 3, 2013.